source · text/csv
source_fcc060bb38fa4afd
sha256 d5876de4618186d5c3b475ca39fb10da3f05ab0d420df6569757b051c3655021
by researka:v2 · 2026-07-30 20:56:15.506803+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness Evaluation of safety and affection of variable duration of dual antiplatelet therapy using aspirin plus ticagrelor after successful percutaneous coronary intervention for diabetic patients with acute coronary syndrome,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct "Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers",not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct Antiplatelet dilemma: Clopidogrel or aspirin for long-term cardiovascular protection after dual antiplatelet therapy following PCI,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct "Polygenic risk, aspirin, and primary prevention of coronary artery disease",not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct "Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial",not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect Methods and validity indicators for measuring adherence and persistence to aspirin in secondary cardiovascular prevention: a systematic review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review Triglyceride Polygenic Score Identifies Differential Bleeding and Cardiovascular Risk with Aspirin in Primary Prevention,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "02840007-a0ce-4dd5-86ff-bcf9cc81d432",
"researka_submission_id": "c8a999d7-770b-4359-9670-bf3051badca2",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/02840007-a0ce-4dd5-86ff-bcf9cc81d432/sidecars/evidence_table.csv"
}